Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial (vol 382, e070464, 2023)

被引：0
|
作者：
不详
机构：
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2023年 / 382卷
关键词：
D O I：
10.1136/bmj.p2193
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
    Pitisuttithum, Punnee
    Luvira, Viravarn
    Lawpoolsri, Saranath
    Muangnoicharoen, Sant
    Kamolratanakul, Supitcha
    Sivakorn, Chaisith
    Narakorn, Piengthong
    Surichan, Somchaiya
    Prangpratanporn, Sumalee
    Puksuriwong, Suttida
    Lamola, Steven
    Mercer, Laina D.
    Raghunandan, Rama
    Sun, Weina
    Liu, Yonghong
    Carreno, Juan Manuel
    Scharf, Rami
    Phumratanaprapin, Weerapong
    Amanat, Fatima
    Gagnon, Luc
    Hsieh, Ching-Lin
    Kaweepornpoj, Ruangchai
    Khan, Sarwat
    Lal, Manjari
    McCroskery, Stephen
    McLellan, Jason
    Mena, Ignacio
    Meseck, Marcia
    Phonrat, Benjaluck
    Sabmee, Yupa
    Singchareon, Ratsamikorn
    Slamanig, Stefan
    Suthepakul, Nava
    Tcheou, Johnstone
    Thantamnu, Narumon
    Theerasurakarn, Sompone
    Tran, Steven
    Vilasmongkolchai, Thanakrit
    White, Jessica A.
    Bhardwaj, Nina
    Garcia-Sastre, Adolfo
    Palese, Peter
    Krammer, Florian
    Poopipatpol, Kittisak
    Wirachwong, Ponthip
    Hjorth, Richard
    Innis, Bruce L.
    ECLINICALMEDICINE, 2022, 45
  • [22] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial (vol 21, pg 637, 2021)
    Ella, R.
    Vadrevu, K. M.
    Jogdand, H.
    LANCET INFECTIOUS DISEASES, 2023, 23 (03): : E80 - E80
  • [23] Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years
    Gholami, Fatemeh
    Farahani, Ramin Hamidi
    Rahjerdi, Ahmad Karimi
    Ahi, Mohammadreza
    Sheidaei, Ali
    Gohari, Kimiya
    Rahimi, Zahra
    Ansarifar, Akram
    Basiri, Pouria
    Moradi, Milad
    Jahangiri, Arash
    Naderi, Kosar
    Ghasemi, Soheil
    Khatami, Pezhman
    Honari, Mohsen
    Khodaverdloo, Samane
    Shooshtari, Mohammad
    Azin, Hajar Mehr
    Moradi, Sohrab
    Shafaghi, Batool
    Allahyari, Hossein
    Monazah, Arina
    Poor, Ali Khodaei
    Taghva, Zahra
    Bakhshande, Hooman
    Nia, Mohammad Karimi
    Dodaran, Masoud Solaymani
    Forooghizade, Mohsen
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [24] Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials
    Liu, Jiankai
    Huang, Baoying
    Li, Guifan
    Huang, Tao
    Wang, Danni
    Zhang, Li
    Deng, Yao
    Chang, Xianyun
    Liu, Yafei
    Li, Weiqi
    Zhang, Siyuan
    Huang, Weijin
    Tan, Wenjie
    Gao, Lidong
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (12) : 1136 - 1142
  • [25] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
    Guo, Wanshen
    Duan, Kai
    Zhang, Yuntao
    Yuan, Zhiming
    Zhang, Yan-Bo
    Wang, Zejun
    Zhao, Dongyang
    Zhang, Huajun
    Xie, Zhiqiang
    Li, Xinguo
    Peng, Cheng
    Zhang, Wei
    Yang, Yunkai
    Chen, Wei
    Gao, Xiaoxiao
    You, Wangyang
    Wang, Xue-Wei
    Shi, Zhengli
    Wang, Yanxia
    Yang, Xu-Qin
    Zhang, Lianghao
    Huang, Lili
    Wang, Qian
    Lu, Jia
    Yang, Yong-Li
    Guo, Jing
    Zhou, Wei
    Wan, Xin
    Wu, Cong
    Wang, Wenhui
    Du, Jianhui
    Nian, Xuanxuan
    Li, Xing-Hang
    Huang, Shihe
    Shen, Shuo
    Xia, Shengli
    Pan, An
    Yang, Xiaoming
    ECLINICALMEDICINE, 2021, 38
  • [26] Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Zhu, Feng-Cai
    Meng, Fan-Yue
    Li, Jing-Xin
    Li, Xiu-Ling
    Mao, Qun-Ying
    Tao, Hong
    Zhang, Yun-Tao
    Yao, Xin
    Chu, Kai
    Chen, Qing-Hua
    Hu, Yue-Mei
    Wu, Xing
    Liu, Pei
    Zhu, Lin-Yang
    Gao, Fan
    Jin, Hui
    Chen, Yi-Juan
    Dong, Yu-Ying
    Liang, Yong-Chun
    Shi, Nian-Min
    Ge, Heng-Ming
    Liu, Lin
    Chen, Sheng-Gen
    Ai, Xing
    Zhang, Zhen-Yu
    Ji, Yu-Guo
    Luo, Feng-Ji
    Chen, Xiao-Qin
    Zhang, Ya
    Zhu, Li-Wen
    Liang, Zheng-Lun
    Shen, Xin-Liang
    LANCET, 2013, 381 (9882): : 2024 - 2032
  • [27] Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
    Hernandez-Bernal, Francisco
    Ricardo-Cobas, Maria C.
    Martin-Bauta, Yenima
    Navarro-Rodriguez, Zadis
    Pinera-Martinez, Marjoris
    Quintana-Guerra, Joel
    Urrutia-Perez, Karen
    Urrutia-Perez, Klaudia
    Chavez-Chong, Cristina O.
    Azor-Hernandez, Jorge L.
    Rodriguez-Reinoso, Jose L.
    Lobaina-Lambert, Leonardo
    Colina-Avila, Elizabeth
    Bizet-Almeida, Jacqueline
    Rodriguez-Nuviola, Jeniffer
    del Valle-Pinera, Sergio
    Ramirez-Dominguez, Mayara
    Tablada-Ferreiro, Elisangela
    Alonso-Valdes, Marel
    Lemos-Perez, Gilda
    Guillen-Nieto, Gerardo E.
    Palenzuela-Diaz, Ariel
    Noa-Romero, Enrique
    Limonta-Fernandez, Miladys
    Fernandez-Avila, Juan M.
    Ali-Mros, Nabil A.
    del Toro-Lahera, Lianne
    Remedios-Reyes, Rossana
    Ayala-Avila, Marta
    Muzio-Gonzalez, Verena L.
    ECLINICALMEDICINE, 2022, 46
  • [28] Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
    Khobragade, Akash
    Bhate, Suresh
    Ramaiah, Vijendra
    Deshpande, Shrikant
    Giri, Krishna
    Phophle, Himanshu
    Supe, Pravin
    Godara, Inderjeet
    Revanna, Ramesh
    Nagarkar, Rajnish
    Sanmukhani, Jayesh
    Dey, Ayan
    Rajanathan, T. M. Chozhavel
    Kansagra, Kevinkumar
    Koradia, Parshottam
    LANCET, 2022, 399 (10332): : 1313 - 1321
  • [29] Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials
    Ozdarendeli, Aykut
    Sezer, Zafer
    Pavel, Shaikh Terkis Islam
    Inal, Ahmet
    Yetiskin, Hazel
    Kaplan, Busra
    Uygut, Muhammet Ali
    Bayram, Adnan
    Mazicioglu, Mumtaz
    Unuvar, Gamze Kalin
    Yuce, Zeynep Ture
    Aydin, Gunsu
    Aslan, Ahmet Furkan
    Kaya, Refika Kamuran
    Koc, Rabia Cakir
    Ates, Ihsan
    Kara, Ates
    VACCINE, 2023, 41 (02) : 380 - 390
  • [30] Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial
    Thiem, Vu Dinh
    Anh, Dang Duc
    Ha, Vu Hai
    Thom, Nguyen Van
    Thang, Tran Cong
    Mateus, Jose
    Carreno, Juan Manuel
    Raghunandan, Rama
    Huong, Nguyen Mai
    Mercer, Laina D.
    Flores, Jorge
    Escarrega, E. Alexandar
    Raskin, Ariel
    Thai, Duong Huu
    Be, Le Van
    Sette, Alessandro
    Innis, Bruce L.
    Krammer, Florian
    Weiskopf, Daniela
    VACCINE, 2025, 44
12345